HCW Biologics (HCWB) Non Operating Interest Expenses (2022 - 2026)

HCW Biologics (HCWB) has reported Non Operating Interest Expenses for 5 consecutive years, with $100541.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 56.04% year-over-year to $100541.0; the trailing twelve-month figure through Jun 2026 stood at $668453.0 (down 31.37% YoY), and the FY2025 full-year result was $845051.0, up 29.16% from the prior year.
• Non Operating Interest Expenses eased to $100541.0 in Q2 2026 per HCWB's latest filing, from $212128.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $260376.0 in Q4 2024 and bottomed at -$1423.0 in Q4 2023.
• Historically, Non Operating Interest Expenses has averaged $141648.4 across 5 years, with a median of $113805.5 in 2025.
• The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses slumped 101.51% in 2023, then jumped 18397.68% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $94476.0 in 2022, then tumbled by 101.51% to -$1423.0 in 2023, then surged by 18397.68% to $260376.0 in 2024, then slipped by 18.53% to $212128.0 in 2025, then plunged by 52.6% to $100541.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $100541.0, $212128.0, and $127070.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.